Hepatocellular Carcinoma Clinical Trials in Oklahoma City, Oklahoma

3 studies are recruiting for hepatocellular carcinoma in Oklahoma City, Oklahoma right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

    This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Oklahoma City, Oklahoma
    Locations
    219 in total
    Run by
    AstraZeneca

    See if you can join NCT06921785 on ClinicalTrials.gov

  2. A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

    The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolera…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
    Locations
    21 in total
    Run by
    Tvardi Therapeutics, Incorporated

    See if you can join NCT05440708 on ClinicalTrials.gov

  3. Combination of TATE and PD-1 Inhibitor in Liver Cancer

    This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellula…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    University of Oklahoma Health Science Center, Oklahoma City, Oklahoma
    Locations
    3 in total
    Run by
    Teclison Ltd.

    See if you can join NCT03259867 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.